Acelyrin PsA Data Are Positive, But Is Its IL-17 Blocker Competitive?

 
• By Joseph Haas
Psoriatic arthritis
Acelryin hopes izokibep will be competitive in the PsA space • Source: Shutterstock

More from Clinical Trials

More from R&D